All In MedTech

FDA Clearance Tracker · P000027

ELECSYS FREE PSA IMMUNOASSAY/CALSET/CALCHECK

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Dec 12, 2000 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Dec 12, 2000

Approved

Time to decision

158 days

Received Jul 7, 2000. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class II

The decision

FDA number
P000027
Device name
ELECSYS FREE PSA IMMUNOASSAY/CALSET/CALCHECK
Applicant location
Indianapolis, IN
Received
Jul 7, 2000
Decided
Dec 12, 2000
Decision
Approved
Supplements
42 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class II
Regulation
21 CFR 866.6010

Every decision under product code LTJ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE ELECSYS(R) FREE PSA IMMUNOASSAY FOR ELECSYS 1010 AND 2010 IMMUNOASSAY ANALYZERS. THE DEVICE IS INDICATED FOR: THE IN VITRO QUANTITATIVE DETERMINATION OF FREE PROSTATE-SPECIFIC ANTIGEN IN HUMAN SERUM AND PLASMA. THE ELECSYS FREE PSA IMMUNOASSAY IS INDICATED FOR MEASUREMENT OF FPSA IN CONJUNCTION WITH THE ELECSYS TOTAL PSA ASSAY TO DEVELOP A RATIO (% FPSA) OF FPSA TO TPSA. THIS RATIO IS USEFUL WHEN USED IN CONJUNCTION WITH THE ELECSYS TOTAL PSA TEST AS AN AID IN DISTINGUISHING PROSTATE CANCER FROM BENIGN PROSTATIC CONDITIOND IN MEN AGE 50 YEARS OR OLDER WHO HAVE A DIGITAL RECTOAL EXAMINATION (DRE) THAT IS NOT SUSPICIOUS FOR PROSTATE CANCER AND AN ELECSYS TOTAL PSA VALUE IN THE RANGE 4 NG/ML TO 10 NG/ML. PROSTATE BIOPSY IS REQUIRED FOR THE DIAGNOSIS OF PROSTATE CANCER. THE ELECTROCHEMILUMINESCENE IMMUNOASSAY "ECLIA" IS INTENDED FOR USE ON THE ROCHE ELECSYS 1010 AND 2010 IMMUNOASSAY ANALYZERS.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LTJ. The earliest in FDA's data is P850048-S002, decided Jul 10, 1987.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Roche Diagnostics Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.